Public healthcare companies in the biotechnology, life science tools, diagnostics, and medical technology sectors are scheduled to engage with institutional investors at the 5th Annual ROTH Healthcare Opportunities Conference.
The event, hosted by ROTH Capital Partners, will be held at The Metropolitan Club in New York City on Sept. 29. B2i Digital, Inc. is serving as the marketing partner for the conference, providing support through digital marketing, its media network, social media, and company profiles.
The conference program is centered on management engagement, featuring 25-minute one-on-one and small group meetings. These sessions are scheduled to run from 8 a.m. to 4:30 p.m., providing institutional clients with access to C-level executives from various public healthcare companies.
The event will feature several specialized panels. A session focused on frontiers in neuroscience will include representatives from Annovis Bio, CervoMed, Gain Therapeutics, MediciNova, and ProMIS Neurosciences. Dr. Frank Lichtenberg, a professor emeritus of healthcare management at Columbia University, is scheduled to discuss the economics of drug value and its implications for pricing and coverage.
Additional panels will address the biotechnology sector’s regulatory uncertainty and capital constraints, featuring Kendall Square Policy Strategies, PolyPid, and Newron Pharmaceuticals. A discussion on the rise of minimal residual disease monitoring in solid tumors will also take place, with participation from Biodesix, DeciBio, and Memorial Sloan Kettering Cancer Center.
Confirmed participants include a diverse array of companies, featuring 908 Devices Inc., Akari Therapeutics Plc, Alpha Teknova, Inc., Annovis Bio, Inc., Arcturus Therapeutics Holdings Inc., BioAge Labs, Inc., Biodesix, Inc., CapsoVision, Inc., CervoMed Inc., Cingulate Therapeutics, Clene Inc., Eos SENOLYTIX, Equillium, Inc., Gain Therapeutics, Inc., MAXONA Pharmaceuticals, Inc., MediciNova, Inc., Medicus Pharma Ltd., Moleculin Biotech, Inc., NeuroSense Therapeutics Ltd., Newron Pharmaceuticals S.p.A., OS Therapies Incorporated, Ovid Therapeutics Inc., Polaryx Therapeutics, Inc., PolyPid Ltd., ProMIS Neurosciences Inc., Rapid Micro Biosystems, Inc., Revelation Biosciences, Inc., Serina Therapeutics, Inc., Stereotaxis, Inc., Trulieve Cannabis Corp., and vTv Therapeutics, Inc.
The conference is an invitation-only event, and all registration is subject to approval by ROTH.
